P/E at 31.4 vs Industry's 37.44: What the Data Shows for Dr Reddys Laboratories Ltd

1 hour ago

Share Via

A price-to-earnings ratio of 31.4 against an industry average of 37.44 marks a notable valuation discount for Dr Reddys Laboratories Ltd. Previously rated Hold by MarketsMojo, the stock’s rating was reassessed on 13 Jul 2026. While the one-year return slightly outperforms the Sensex, the three-month performance reveals a sharper decline, signalling a divergence in momentum that merits closer examination.

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 31.4, which is approximately 16% below the Pharmaceuticals & Biotechnology industry average of 37.44. This discount suggests the market is pricing in either a relative undervaluation or concerns about near-term earnings growth compared to peers. The sector’s elevated P/E reflects investor willingness to pay a premium for growth and innovation, yet Dr Reddys Laboratories Ltd remains comparatively conservative in valuation terms. Is this valuation gap signalling a buying opportunity or a justified caution? The answer lies in the interplay of performance and technical indicators.

Performance Across Timeframes: Mixed Signals

Examining returns over various periods reveals a nuanced picture. Over the past year, Dr Reddys Laboratories Ltd has declined by 7.29%, marginally outperforming the Sensex’s 8.93% fall. This relative resilience is more pronounced when looking at the year-to-date (YTD) performance, where the stock’s loss of 4.58% contrasts favourably with the Sensex’s steeper 12.27% decline. However, the short-term momentum tells a different story: the stock has fallen 6.80% over the last three months, underperforming the Sensex’s 1.88% drop. This divergence suggests recent headwinds have weighed more heavily on the stock, despite a stronger medium-term showing. Is this a temporary setback or indicative of deeper challenges?

Shorter-term returns offer some relief. The stock gained 5.90% over the past week, significantly outpacing the Sensex’s 0.58% rise, and posted a 3.22% gain over the last month compared to the Sensex’s 3.58% decline. The one-day performance is largely inline with the sector, up 0.07% versus the Sensex’s 0.32% gain. These fluctuations highlight a stock experiencing bouts of volatility and short-term recovery attempts amid a broader downtrend.

Moving Average Configuration: Signs of a Partial Recovery

The technical setup for Dr Reddys Laboratories Ltd reveals a mixed trend. The stock price currently sits above its 5-day, 20-day, and 50-day moving averages, signalling short-term strength and a recent bounce. However, it remains below the 100-day and 200-day moving averages, which typically represent longer-term trend resistance. This configuration often indicates a recovery attempt within a larger downtrend, where the stock is testing resistance levels but has yet to confirm a sustained uptrend. The 5% surge partially reverses a 6.8% quarterly decline — is this a genuine recovery or a relief rally that will fade at the 100 DMA? The moving average configuration provides the clearest answer.

Sector Performance Context

The Pharmaceuticals & Biotechnology sector has seen mixed results in recent earnings seasons. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution suggests a sector grappling with uneven growth and varying company-specific challenges. Within this context, Dr Reddys Laboratories Ltd’s performance and valuation discount may reflect cautious investor sentiment amid sector-wide uncertainties.

Rating Reassessment: Previously Hold, Now Reassessed

MarketsMOJO had previously rated Dr Reddys Laboratories Ltd as Hold. The rating was updated on 13 Jul 2026, reflecting the evolving data landscape. While the current rating is undisclosed, the reassessment aligns with the stock’s recent performance trends and valuation profile. Previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? The four-parameter analysis factors in the valuation premium, performance divergence, moving average configuration, and sector context to provide a comprehensive view.

Longer-Term Performance: A Mixed Legacy

Looking beyond the immediate horizon, Dr Reddys Laboratories Ltd has delivered a 5-year return of 26.44%, slightly outperforming the Sensex’s 24.85% gain over the same period. However, the 3-year return of 9.93% lags behind the Sensex’s 13.27%, and the 10-year return of 90.63% trails the Sensex’s 160.80% substantially. These figures illustrate a stock that has historically delivered solid but not spectacular returns relative to the broader market, with recent years showing some deceleration in relative performance.

Conclusion: What the Data Collectively Shows

The data on Dr Reddys Laboratories Ltd paints a picture of a stock trading at a valuation discount to its sector, with a mixed performance profile that combines medium-term weakness and short-term recovery attempts. The moving average configuration supports the view of a tentative bounce within a longer-term downtrend, while sector results remain uneven. The rating reassessment from Hold reflects these complexities. Should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider? The current rating provides the answer.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE